PP
MRNS

Paloma Partners’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Paloma Partners’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-62,400
Closed -$73K – 1800
2024
Q2 		$73K Buy
+62,400
New +$156K ﹤0.01% 1112

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Paloma Partners's MRNS Position: Q3 2024 in Review

Paloma Partners sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2024, closing a stake of 62,400 shares — an estimated $73K sold.

Paloma Partners first reported a position in MRNS in Q2 2024 and held it in 1 quarter. The position peaked at $73K in Q2 2024. 75 funds tracked by Wall St. Rank hold MRNS as of Q3 2024.

  • Paloma Partners reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 62,400 Marinus Pharmaceuticals, Inc shares in Q3 2024, an estimated $73K.
  • Paloma Partners first reported a position in Marinus Pharmaceuticals, Inc in Q2 2024 and held it in 1 quarter.
  • Paloma Partners's Marinus Pharmaceuticals, Inc position peaked at $73K in Q2 2024.
  • 75 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.